Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 29;13(1):1.
doi: 10.3390/pharmacy13010001.

Empowering Patient Safety: Assessment of Adverse Drug Reaction Knowledge and Practice Among Pharmacy Professionals

Affiliations

Empowering Patient Safety: Assessment of Adverse Drug Reaction Knowledge and Practice Among Pharmacy Professionals

Josipa Bukić et al. Pharmacy (Basel). .

Abstract

Despite technological advancements, healthcare professionals must actively prioritize patient safety. Reporting adverse drug reactions is a critical aspect of this responsibility, and the most accessible healthcare providers, community pharmacists, and pharmacy technicians play a key role. Therefore, this study assessed their knowledge and practices regarding adverse drug reaction reporting in Croatia. A total of 180 participants were included. Pharmacists demonstrated significantly better knowledge than technicians (94.78 vs. 73.97, p = 0.024). Chronic medication users also showed greater understanding compared to non-users (104.96 vs. 85.39, p = 0.021). Knowledge improved with the number of adverse drug reactions reported, and most participants (72.78%) had reported adverse drug reactions. Pharmacists were 83.60% more likely to report adverse drug reactions than technicians (p < 0.001). These findings reveal a gap in pharmacy technicians' integration into pharmacovigilance, underscoring a need to strengthen their role in adverse drug reaction reporting and patient safety.

Keywords: adverse drug reaction; drug safety; pharmacists; pharmacovigilance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Similar articles

References

    1. Sabaté M., Montané E. Pharmacoepidemiology: An Overview. J. Clin. Med. 2023;12:7033. doi: 10.3390/jcm12227033. - DOI - PMC - PubMed
    1. World Health Organization What Is Pharmacovigilance? [(accessed on 2 October 2024)]. Available online: https://www.who.int/teams/regulation-prequalification/regulation-and-saf....
    1. European Medicines Agency Good pharmacovigilance practices (GVP) [(accessed on 2 October 2024)]. Available online: https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisatio....
    1. Khan M.A.A., Hamid S., Babar Z.-U.-D. Pharmacovigilance in High-Income Countries: Current Developments and a Review of Literature. Pharmacy. 2023;11:10. doi: 10.3390/pharmacy11010010. - DOI - PMC - PubMed
    1. Leskur D., Bozic J., Rusic D., Seselja Perisin A., Cohadzic T., Pranic S., Modun D., Bukic J. Adverse drug reaction reporting via mobile applications: A narrative review. Int. J. Med. Inform. 2022;168:104895. doi: 10.1016/j.ijmedinf.2022.104895. - DOI - PubMed

LinkOut - more resources